

# Jun Zhao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7881984/jun-zhao-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71  
papers

2,379  
citations

17  
h-index

48  
g-index

83  
ext. papers

3,542  
ext. citations

5.5  
avg, IF

4.2  
L-index

#	Paper	IF	Citations
71	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.. <i>Targeted Oncology</i> , <b>2022</b> , 17, 1-13	5	3
70	Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma.. <i>Journal of Cancer</i> , <b>2022</b> , 13, 1565-1572	4.5	0
69	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based p.T790M in non-small-cell lung cancer patients. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3888-3901	4.4	3
68	Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. <i>BMC Cancer</i> , <b>2021</b> , 21, 1107	4.8	1
67	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1813-1821	2.6	0
66	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 709-717	13.4	45
65	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 639892	5.6	5
64	A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21053-e21053	2.2	1
63	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 690093	5.3	1
62	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 709877	5.3	1
61	First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	6
60	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 305-314	35.1	70
59	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1296-1304	12.9	32
58	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 33	3.2	7
57	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 281-284	4.4	4
56	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1799-1812	2.6	0
55	Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2825-2828	3.2	3

54	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1403-1414	8.9	0
53	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , <b>2020</b> , 20, 590	6.4	
52	Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 729	5.3	7
51	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , <b>2020</b> , 145, 140-143	5.9	5
50	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study <b>2020</b> , 8,		30
49	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1149-1159	3.2	2
48	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 626	5.3	5
47	Pyrotinib in -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2753-2761	2.2	49
46	Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 754-761	3.2	5
45	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 892-901	12.9	34
44	BRAF fusion in lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21598-e21598	2.2	0
43	Co-mutation features in treatment-naïve EGFR-mutant lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21616-e21616	2.2	
42	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3641-3644	3.2	2
41	KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3425-3435	3.2	5
40	Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e258-e260	4.9	9
39	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , <b>2020</b> , 20, 666	4.8	8
38	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1137	5.3	3
37	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , <b>2020</b> , 147, 259-268	5.9	9

36	Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1568	5.3	1
35	A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1507-1515	4.4	3
34	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 793	4.8	6
33	Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 37	22.4	12
32	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 574752	5.3	3
31	Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. <i>Lung Cancer</i> , <b>2019</b> , 135, 116-122	5.9	6
30	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5049-5060	12.9	31
29	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 1819-1830	40	1272
28	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1193-1202	3.2	4
27	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1788-1797	3.2	5
26	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2081-2087	3.2	6
25	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2088-2095	3.2	14
24	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 459-471	3.2	8
23	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. <i>Cancer Letters</i> , <b>2019</b> , 440-441, 180-188	9.9	12
22	Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel $\alpha_1$ Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2148-2158	12.9	29
21	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 291-297	3.2	4
20	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1166-1173	3.2	7
19	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , <b>2018</b> , 7, 428-436	4.4	5

18	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , <b>2018</b> , 18, 1171	4.8	17
17	Ectopic Cushing syndrome in small cell lung cancer: A case report and literature review. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 114-117	3.2	12
16	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1376-1387	8.9	29
15	A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma. <i>Molecular Therapy - Nucleic Acids</i> , <b>2017</b> , 6, 269-278	10.7	27
14	Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 138-146	3.2	10
13	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2017</b> , 29, 553-560	3.8	10
12	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1766-1778	8.9	35
11	Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer. <i>International Journal of Biological Markers</i> , <b>2017</b> , 32, e267-e273	2.8	6
10	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2016</b> , 28, 12-8	3.8	1
9	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 20810-24	3.3	63
8	Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 1851-6	5.6	14
7	Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 509-16	3.2	9
6	Patterns and prognosis of locally recurrent rectal cancer following multidisciplinary treatment. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 7015-20	5.6	22
5	Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1324-30	12.9	85
4	High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2010</b> , 22, 296-302	3.8	1
3	A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2009</b> , 21, 111-116	3.8	2
2	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2653-9	2.2	237
1	Community Dynamics of Seed Rain in Mixed Evergreen Broad-leaved and Deciduous Forests in a Subtropical Mountain of Central China. <i>Journal of Integrative Plant Biology</i> , <b>2007</b> , 49, 1294-1303	8.3	6

